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ABSTRACT
Clinical research into chronic graft-versus-host disease (GVHD) lags behind that in other areas in the field.
Interest in chronic GVHD has increased significantly in recent years for various reasons, including advances in
biotechnology, a perceived increase in the incidence of chronic GVHD, and decreased regimen-related
mortality, resulting in a new emphasis on quality of life and absence of disability as endpoints of major
significance in transplantation survivors. In this overview, we address 3 key areas related to chronic GVHD that
hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy.
© 2007 American Society for Blood and Marrow Transplantation
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Chronic graft-versus-host disease (GVHD), a
rimary late complication of allogeneic hematopoi-
tic stem cell transplantation (alloSCT), has been
ifﬁcult to address, and research lags behind clinical
eeds [1]. Interest in chronic GVHD has increased
igniﬁcantly in recent years due to various reasons,
ncluding (1) advances in biotechnology that have
aised hopes for more effective prevention and ther-
pies for this disorder, as well as better opportuni-
ies for deciphering the chronic GVHD–associated
ntitumor effects; (2) a possible increase in the in-
idence of chronic GVHD due to changing patterns
f alloSCT use; and (3) decreased nonrelapse mor-
ality in alloSCT, which has created a stronger
mphasis on quality of life and absence of disability
s clinical endpoints of major interest in transplan-
ation survivors. In this overview we address 3 key
reas related to chronic GVHD that currently draw
he most dynamic research activity and hold the
ighest promise for major advances in the near
uture: pathobiology, response criteria, and therapy.
ore comprehensive reviews and updates onhronic GVHD are available elsewhere [2-10]. iHRONIC GVHD PATHOBIOLOGY: WHAT WE REALLY
NOW AND HOW WE CAN LEARN MORE
Chronic GVHD remains a major source of mor-
idity and mortality in alloSCT, yet relatively little is
nown about its pathobiology. This is due in part to
he absence of animal models that can recreate the
linical scenario of chronic GVHD—delayed onset,
revious or current immunosuppression, and often
revious acute GVHD, even though some models
particularly the B10.D2/BALB/c strain pairing) do
apture some of the human histological features [11].
his is in contrast to acute GVHD, in which animal
odels have been used more successfully in dissecting
echanisms of alloimmunity. A number of thoughtful
ypotheses to explain chronic GVHD have been sug-
ested; generating compelling data that clearly sup-
ort or refute speciﬁc mechanisms has proven difﬁ-
ult.
For what factors do hypotheses for chronic
VHD pathogenesis need to account? The short list
s basically a recapitulation of risk factors and key
linical features: relatively late onset, acute GVHD as
he major risk factor, the ability of donor leukocyte
nfusions to induce a chronic GVHD-like syndrome
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Advances in Chronic Graft-versus-Host Disease 3e novo, and protean manifestations. The diversity of
linical presentations is one of the most interesting
eatures of chronic GVHD. The clinical presentations
an be so distinct that although they tend to occur
elatively late posttransplantation, it may be helpful to
lso consider the more common presentations (eg,
ichenoid skin disease, scleroderma-like skin disease,
icca syndrome, eosinophilic fasciitis) as distinct enti-
ies with separate pathogenic mechanisms.
A fundamental question is what are the target
ntigens of chronic GVHD–inducing immune cells?
he simplest answer is that, as in acute GVHD, minor
istocompatibility (H) antigens are the main targets. If
his is so, then questions regarding pathogenesis
ould focus on why targeting of minor H antigens can
esult in chronic GVHD rather than acute GVHD
see below). Some authors have speculated that
hronic GVHD is an “autoimmune” disease, however
12]. This implies that the target antigens are not
inor H antigens, but rather nonpolymorphic anti-
ens expressed in both the donor and recipient.
A twist on this hypothesis is that the pathogenic
cells could be derived from donor precursors that
ature in the recipient thymus instead of being prog-
ny of infused mature T cells. The idea here is that
efective central negative selection leads to the gen-
ration of autoreactive clones that escape toleragenic
echanisms operating in the periphery [13]. The con-
ecture that the antigen is a self-antigen is plausible, in
hat T cells reactive to at least 1 nonpolymorphic
ntigen, the PR1 epitope of proteinase 3, which is
verexpressed in chronic myelogenous leukemia cells,
ave been demonstrated. Moreover, in mice and hu-
ans it is clear that there is an autoreactive repertoire,
nd the development of autoimmunity may reﬂect a
ailure in regulatory mechanisms other than central or
eripheral deletion of self-reactive T cells. In the
xtreme example when major regulatory mechanisms
re impaired (eg, murine genetic deﬁciencies in FoxP3
nd CTLA4 [14,15] or treatment of humans with a
locking antibody to CTLA4), T cell–mediated tissue
estruction is severe. It is conceivable that regulatory
echanisms may frequently fail in alloSCT, resulting
n activation and expansion of T cells that recognize
onpolymorphic epitopes.
What types of evidence could support this hypoth-
sis? At a minimum, isolation of donor-derived T-cell
lones that equally recognize donor and recipient cells
hould be demonstrated. The frequency of such clones
ould be increased in recipients with chronic GVHD
ompared with otherwise similar recipients without it.
deally, these T cells would be used as probes to
dentify the target antigens and thereby provide mo-
ecular proof of reactivity against nonpolymorphic an-
igens. This might also provide insight into why a
onpolymorphic as opposed to a minor H antigen
ould cause chronic GVHD. Clones that recognize plloantigens have been derived from T cells harvested
rom patients with chronic GVHD. However, this
oes not exclude the presence of “autoreactive”
cells; to intentionally attempt to isolate autoreactive
cells, stimulators used to expand donor T cells
hould be donor-derived, not host-derived. This hy-
othesis would also need to explain the absence of
igniﬁcant chronic GVHD in autotransplant recipi-
nts, even with cyclosporine treatment; that is, there is
omething about the presence of alloreactivity and
mmunosuppression that would precipitate the gener-
tion of autoreactive T cells.
Whether the antigen is auto or allo, another “an-
igen” question is whether a speciﬁc antigen or type of
arget antigen is required for chronic GVHD. In a
urine model that recreates histological features of
utaneous chronic GVHD, we found evidence that
he development of that syndrome is target antigen–
ependent [16]. We compared GVHD in 3 major
istocompatibility complex (MHC)–congenic donor
ecipient pairs. We reasoned that the different MHCs
ould present different sets of peptides in both the
onor and recipient, and in the donor would select for
istinct T-cell receptor repertoires. The net effect
ould be that in each donor–recipient pair, different
mmunodominant antigens would likely be targeted,
ut all other genes outside of the MHC loci would be
dentical. Indeed, we observed 3 distinct forms of
VHD in each donor–recipient pair, suggesting that
he choice of target antigen(s) was capable of driving 3
istinct GVHD phenotypes. However, if this is also
rue in humans, then it seems likely that the choice of
ntigen must be somewhat promiscuous, because so
any patients develop some form of chronic
VHD—yet there is no clear HLA association, which
ould be anticipated if a speciﬁc chronic GVHD syn-
rome required the targeting of a speciﬁc antigen.
Chronic GVHD could also be a product of T cells
hat have undergone relatively chronic antigen stim-
lation. That is, under circumstances of chronic anti-
en stimulation, responding T cells can induce syn-
romes resembling those induced by the chronic
ntigen stimulation in autoimmune diseases. This
oncept is also consistent with the proposal of acute
VHD as a risk factor for chronic GVHD. The
inor H antigens targeted in chronic GVHD could
e the same dominant ones targeted in acute GVHD,
ut the reactive T cells could be different; for exam-
le, they may secrete transforming growth factor- or
nterleukin-5. However, antigens other than those
hat were initially immunodominant, even those not
nitially targeted but introduced through epitope
pread, could be important.
Part of chronic GVHD pathogenesis could be a
onsequence of T cell priming by donor-derived an-
igen-presenting cells (APCs). Chronic GVHD, be it
rogressive, de novo, or occurring after donor lym-
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W. D. Shlomchik et al.4hocyte infusion, clearly occurs when APCs are nearly
ntirely donor in origin. Presentation on donor-de-
ived APCs might predict a more dominant role for
D4 cells, because exogenous antigen is more efﬁ-
iently presented on MHC-II than on MHC-I. Con-
istent with this, in a murine chronic GVHD model
e found that exclusive donor T-cell activation by
onor-derived APCs was sufﬁcient for cutaneous
VHD [17]. Responses to rituximab [18], which tar-
ets donor-derived B cells, argues for meaningful an-
igen presentation and T-cell priming by donor B cells
n at least a subset of patients. This is also consistent
ith prior evidence for a role of B cells in priming
athogenic T cells in murine models in autoimmune
isease [19] and responses to rituximab in patients
ith systemic lupus erythematosus and rheumatoid
rthritis. Consistent with this, the same group identi-
ed immunoglobulin class–shifted antibodies to mi-
or H antigens in patients with chronic GVHD,
hich at a minimum suggests that donor B cells have
ubstantial interactions with donor CD4 cells [20].
nforced indirect presentation could also result in a
ifferent set of antigens than would be presented early
osttransplantation when a substantial number of host
PCs are present and direct presentation is possible. A
kewing toward antigens not expressed by recipient
ematopoietic cells would also be a consequence of
ater T-cell activation.
Another product of late T-cell priming would be
hat responding T cells would likely have already
ndergone lymphopenia-induced proliferation (LIP)
r would continue to be driven by signals that drive
IP. Nearly all donor T cells acquire a phenotype of
aving been previously activated; yet we know that
nly a minority of these are likely to be alloreactive.
IP certainly alters the phenotype of cells to more
esemble memory T cells, and perhaps de novo al-
oantigen stimulation of these cells is more likely to
nduce a chronic GVHD–like syndrome. Such prim-
ng would also occur remote from a conditioning
egimen that also may inﬂuence the phenotype of
esponding T cells.
In summary, hypothesis generation is relatively
asy—studies in humans to test these hypotheses are
uch more difﬁcult. Progress in understanding
hronic GVHDwill require more investigators to take
n the difﬁcult task of performing quality immuno-
ogic studies in humans.
EASURING THERAPEUTIC RESPONSE IN
HRONIC GVHD
Current therapies for chronic GVHD are of lim-
ted efﬁcacy, and there is no long-term satisfactory
egimen for patients who fail front-line steroid-based
herapy. Indeed, there is no Food and Drug Admin- ustration (FDA)-approved medication for use in
hronic GVHD. The lack of standardized response
riteria to measure therapeutic efﬁcacy poses a major
bstacle to pursuing therapeutic trials in chronic
VHD. Overall survival or survival to discontinua-
ion of systemic immunosuppression are accepted
ong-term endpoints in chronic GVHD trials, but
eaching these long-term outcomes may take several
ears, which is not suitable for early-phase drug de-
elopment studies. Qualitative assessments of the
hronic GVHD manifestations most commonly used
n clinical trials can guide our clinical decisions but are
ot reproducible and are inadequate for quantifying
nd comparing responses. The recent National Insti-
utes of Health (NIH)-sponsored consensus project
rovided for the ﬁrst time a set of standardized mea-
ures and deﬁnitions to use as response criteria in
hronic GVHD [3-8]. Such an approach can enhance
niformity of data collection and improve standard-
zation of chronic GVHD clinical trials. Preliminary
vidence suggests these tools may prove to be feasible
nd reproducible [21]. Nonetheless, it is imperative
hat these recommendations be tested and validated in
rospective studies and be subjected to periodic re-
nements. Among the major unresolved questions re-
ains how to develop measures of response in chronic
VHD that can distinguish reversible disease activity
rom the irreversible inactive damage (Figure 1).
The NIH Consensus Conference has deﬁned re-
ponse measures classiﬁed in 2 main groups: clinician-
ssessed and patient-reported (Table 1). These are
urther divided into chronic GVHD-speciﬁc core
easures, which are always recommended for use in
rials, and chronic GVHD nonspeciﬁc ancillary mea-
ures, which are optional and investigational and in-
lude objective measures of physical performance and
atient-reported measures of functional status. In a
omplex disease such as chronic GVHD, ancillary
easures of function could theoretically represent im-
ortant surrogate outcomes and in some situations
ight be more informative than the disease-speciﬁc
easures (eg, advanced skin sclerosis). Measures of
unctional status can also provide corroborative evi-
ence of important changes after therapy. Such out-
omes have been extensively applied in other chronic
isease patient populations.
linician-Assessed Measures in Chronic GVHD
Clinician-assessed measures as proposed by the
IH criteria [6] include the following:
A. Organ-speciﬁc assessments of signs and symp-
oms: (a) skin, calculating percentages of body surface
rea, measuring ulcer size and recording symptom
ntensity; (b) eyes, using Schirmer’s test without an-
sthesia and symptom intensity assessment; (c) mouth,
sing the modiﬁed Schubert oral mucositis scale scor-
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Advances in Chronic Graft-versus-Host Disease 5ng oral surfaces as 0-15, and symptom intensity;
d) hematopoietic parameters, absolute platelet count
nd absolute eosinophil count; (e) gastrointestinal
ymptoms, graded by the examining clinician on se-
erity scales of 0–3; (f) liver function, determined by
he most recent laboratory results; (g) lung measures,
sing forced expiratory volume in the ﬁrst second and
ingle-breath diffusion lung capacity for carbon mon-
xide adjusted for hemoglobin; (i) in women, speciﬁc
uestions relating to vulvar and vaginal symptoms
with patients reporting problems referred to a gyne-
ologist); and (j) musculoskeletal connective tissue as-
essed by active-assisted range of joint motion if an
dequately trained professional is available.
B. Clinician-reported global ratings should pro-
ide an assessment of current overall chronic GVHD
everity on a 4-point scale (none, mild, moderate, or
evere) and on an 11-point numerical scale (0–10), and
lso provide their assessments of patient chronic
VHD changes during the past month scored on a
igure 1. Active versus inactive manifestations of chronic GVHD. (A
re a sign of active disease and usually are reversible. (B) A patient
uch pigment changes are considered inactive and are most commo
f distinguishing active from inactive manifestations in response
ermatology Branch, National Cancer Institute.)
able 1. Summary of Response Measures as Proposed by the NIH Cons
Measure Clinician-Assessed
. Chronic GVHD-specific core measures
Signs Organ-specific measures
Symptoms Clinician-assessed sympto
Global rating Mild, moderate, or severe
0 to 10 severity scale
7-point change scale
I. Chronic GVHD nonspecific ancillary measures
Function Grip strength
2-minute walk time
Quality of life —-point scale, ranging from “very much worse” (3)
o “very much better” (3).[22]
C. Objective measures of physical performance
nclude grip strength, measured using a portable hy-
raulic dynamometer, and the 2-minute walking dis-
ance (measured as velocity divided by total distance
alked in 2 minutes).
D. Although Karnofsky and Lansky performance
cores are not considered sufﬁciently sensitive for
uantifying responses, these scores have historically
rognostic value in chronic GVHD and should be
ecorded as part of each assessment.
atient-Reported Measures in Chronic GVHD
Both acute and chronic GVHD have adverse ef-
ects on functional status and quality of life (QOL),
onsistent with the recognized morbidity of the syn-
rome [23,24]. Deﬁcits occur primarily in physical
nd functional domains (including work, sleep, and
onic GVHD patient with erythematous skin changes. Such changes
stinﬂammatory hyperpigmentation without erythema or sclerosis.
versible. These examples emphasize the importance and challenges
ent. (Courtesy of Dr. Edward Cowen and Dr. Maria Turner,
roject for Clinical Trials in Chronic GVHD6
Patient-Reported
Not applicable
Patient-reported symptoms
Mild, moderate, or severe
0 to 10 severity scale
7-point change scale
Patient-reported function) A chr
with po
nly irre
assessmensus P
msPatient-reported health-related quality of life
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W. D. Shlomchik et al.6njoyment of life), and the symptom burden is high. In
ontrast, patients tend to report adequate social func-
ioning and relatively well preserved emotional well-
eing. Whereas QOL at 6 months is predicted by
revious acute GVHD, QOL at 12 months is most
losely associated with chronic GVHD (Figure 2)
24]. Understanding the effects of chronic GVHD on
atients’ daily lives is important, because chronic
VHD tends to be a chronic, often debilitating syn-
rome. Patient-reported information is critical in the
edical management of patients with chronic
VHD, to best balance tolerance of symptoms with
isks of immunosuppression.
In clinical research, “patient-reported measures”
apture information by asking the patient directly
ather than relying on physical examination ﬁndings,
aboratory results, radiology studies, or physician as-
essment. Although data on symptoms and side effects
an be retrieved from chart review, it is important to
ecognize that this information is usually derived from
hat the patient reported to the physician, who then
ecorded it in the medical record. Major challenges in
igure 2. Mean Trial Outcome Index scores of 3 patient subgro
Reprinted with permission [24].)linical studies include complete collection of patient- aeported information using validated data collection
nstruments and proper biostatistical analysis.
The NIH Consensus Conference recommended
everal patient-reported measures for assessing
hronic GVHD activity [6]. The chronic GVHD
ymptom scale is a validated, 30-item measure that
ssesses the degree of symptom “bother” in the pre-
ious 4 weeks. There are 7 subscales (skin, eyes,
outh, breathing, nutrition, energy, and emotional
istress) and a summary scale, with a possible range of
–100, with higher scores reﬂecting greater symptom
urden [25]. The Consensus Conference also devel-
ped an instrument to capture other symptoms (avail-
ble at http://www.asbmt.org/GvHDForms). Patients
re asked to rate skin itching, mouth dryness, mouth
ain, mouth sensitivity, main eye complaint, and over-
ll chronic GVHD symptom severity on scales of
–10, where 0 is “not present” and 10 is “as bad as you
an imagine.” Females are asked whether they have
ny discomfort in the vagina, vulva, or labia or dyspa-
eunia. Finally, patients are asked to grade their over-
ll chronic GVHD as none, mild, moderate, or severe
fore transplantation and at 6 and 12 months posttransplantation.ups bend to assess whether their chronic GVHD symptoms
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Advances in Chronic Graft-versus-Host Disease 7re better or worse compared with 1 month earlier on
7-point scale ranging from “very much worse” to
very much better.”
Additional measures recommended when assess-
ng adult patients with chronic GVHD include the
uman Activity Proﬁle (HAP), the Functional Assess-
ent of Cancer Therapies–Bone Marrow Transplant
FACT-BMT), and the Medical Outcomes Study
hort Form 36 (SF-36). Children can be assessed with
he Activities Scale for Kids (ASK) and the Child
ealth Ratings Inventories Generic and Disease-Spe-
iﬁc Impairment Inventory–HSCT (CHRIs). Some
nstruments are proprietary and carry usage fees.
Randomized and observational studies have shown
orse QOL when chronic GVHD is present. For
xample, when peripheral blood is used instead of
arrow or allogeneic instead of autologous ap-
roaches, the greater frequency and severity of
hronic GVHD has been associated with worse QOL
26]. In contrast, when chronic GVHD rates are sim-
lar between arms, such as in the National Heart,
ung, and Blood Institute–supported randomized trial
f T-cell depletion in unrelated donor transplants
27], measured QOL is similar [28]. Early outcome
ata suggest that rates of chronic GVHD are similar
n myeloablative and nonmyeloablative approaches
29] and with rapamycin or methotrexate-based
VHD prophylaxis regimens [30], suggesting that
ate QOL may be similar as well. The use of pa-
ient-reported measures is uncommon in therapeu-
ic chronic GVHD studies. A single arm, open-label
tudy of rituximab suggested that patient-reported
utcomes improved in concert with clinical re-
ponses [18].
Collection and analysis of patient self-reported
easures is challenging. Data must be collected in real
ime from cooperative patients; data from surrogates
r patient recollections are inaccurate. Analysis of
ongitudinal, repeated-measures data is complex and
equires speciﬁc expertise and statistical procedures.
ome missing data can be expected, and different
ethods of handling these missing data can affect
onclusions. Finally, interpretation of QOL measure-
ents is not intuitive for many physicians and pa-
ients, and so translating research results into lay lan-
uage that can inform practice is critical.
Chronic GVHD is associated with lower rates of
elapse, and being in remission is associated with bet-
er QOL [31] and longer survival. Thus, total elimi-
ation of chronic GVHD may not be desirable. As
hronic GVHD severity increases, nonrelapse mortal-
ty increases and QOL worsens, but the protection
rom relapse remains the same [32]. The optimal risk-
eneﬁt compromise may be to allow mild chronic
VHD to enable the graft-versus-leukemia effect
hile minimizing the chronic GVHD symptom bur-
en and maintaining the best possible QOL. Incorpo- fation of patient-reported QOL measures sensitive to
hronic GVHD into trials would help clarify ap-
roaches offering the best disease-free survival with
he least toxicity.
HAT IS NEW IN THE TREATMENT OF
HRONIC GVHD
Chronic GVHD is the main long-term complica-
ion and limitation to successful hematopoietic stem
ell transplantation (HSCT). It affects  50% of all
atients undergoing HSCT and most of those with
cute GVHD [33]. Chronic GVHD has a major im-
act on both QOL and survival, frequently involves
ultiple organs, and necessitates prolonged immuno-
uppressive therapy [2]. One report noted that 15% of
ancer-free patients were still receiving immunosup-
ressive therapy after 7 years [34]. The more severe
orms of chronic GVHD are clearly associated with a
ower disease-free survival. Thus, the potential beneﬁt
f a graft-versus-leukemia effect is shadowed by sig-
iﬁcant treatment-related mortality [32].
Chronic GVHD is a disease of deregulated immu-
ity with protean manifestations similar in many ways
o those of autoimmune diseases. The relative uncom-
onness of the disease, the lack of consensus on what
epresents true manifestations of chronic GVHD, the
ery limited understanding of its pathophysiology, and
he clinical complexity of affected patients are all fac-
ors that have hindered a systematic approach to treat-
ng this problem. It is important to recognize that
hronic GVHD is a distinct clinical syndrome, differ-
nt from acute GVHD and the autoimmune disorders
hat it mimics. Strategies that have successfully pre-
ented acute GVHD seem to have little or no impact
n the incidence of chronic GVHD. Approximately
/3 of patients without a history of acute GVHD will
evelop de novo chronic GVHD. On the other hand,
ot all patients affected by acute GVHD will go on to
evelop chronic GVHD. Chronic GVHD mimics
ome aspects of autoimmune conditions, such as sys-
emic lupus erythematosus and scleroderma. How-
ver, the clinical differences here may be just as sig-
iﬁcant as the similarities. Thus, chronic GVHD is a
elatively “autonomous” entity, and the nature of its
ssociation with acute GVHD and similarities with
ther autoimmune disorders remain unclear. Preven-
ion and therapy different from that for any other
ondition within or outside HSCT and deserve sepa-
ate and special consideration.
Unfortunately, the treatment of chronic GVHD is
sually complex, long, and uncertain, and responses
re often partial [34]. Corticosteroids have been and
ontinue to be the mainstay of therapy, providing the
ost effective therapy for chronic GVHD [35]. Un-ortunately, the hurdles associated with prolonged
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W. D. Shlomchik et al.8orticosteroid therapy can be just as harmful as the
isease itself.
Immune tolerance seems to be the ultimate “cure”
or chronic GVHD. A wide variety of systemic, sup-
ortive, and ancillary therapies have been used in the
revention and management of chronic GVHD.
hese strategies are still far from meeting expecta-
ions, however, likely reﬂecting the difﬁculties in har-
essing the immune response toward tolerance.
herefore, current therapy for chronic GVHD is
imed mainly at preventing or suppressing immune-
ediated damage until tolerance occurs.
In this section we emphasize (1) strategies to pre-
ent chronic GVHD, (2) general aspects in the care of
atients with chronic GVHD, and (3) results with the
ore frequently used immunomodulators.
revention of Chronic GVHD
The prevention of acute GVHD has not consis-
ently resulted in a lower incidence of chronic
VHD. A clear example is the use of reduced-inten-
ity transplants, consistently associated with a lower
ncidence of acute GVHD but with no a major impact
n chronic GVHD [29,36]. The extended use of
VHD prophylaxis with cyclosporine, or variations in
he cyclosporine dosage used, showed no beneﬁcial
ffects on the incidence of chronic GVHD [2]. The
ddition of thalidomide to cyclosporine and metho-
rexate prophylaxis in an attempt to preemptively treat
hronic GVHD was evaluated in a placebo-controlled
ouble-blinded study; the thalidomide group had
ore chronic GVHD and worse survival [37]. The
ncorporation of immunoglobulin or early treatment
ased on biopsy ﬁndings of subclinical GVHD also
roved unsuccessful [2]. Of interest, in a small ran-
omized trial, antithymocyte globulin decreased the
isk of chronic GVHD, chronic lung dysfunction, and
ate transplant-related mortality as part of a prepara-
ive regimen, although with no signiﬁcant impact on
urvival or nonrelapse mortality [38].
eneral Aspects in the Treatment of
hronic GVHD
Chronic GVHD is a multisystem disorder that
ost frequently affects multiple organs and also has
sychosocial and sexual aspects in otherwise cancer-
ree patients. The involvement of multiple organs
ictates the need for a multidisciplinary approach co-
rdinated by the transplantation physician, preferably
t a center experienced in the care of these patients.
any larger transplantation centers have clinics de-
oted to the follow-up and care of long-term HSCT
omplications, including GVHD. The participation of
ubspecialists with an interest in and, ideally, experi-
nce with chronic GVHD patients is always desirable
s well. aManagement of chronic GVHD comprises 2 ma-
or aspects, both equally important and intercon-
ected. The ﬁrst component is systemic treatment
ith immunosuppressing and immunomodulating
gents. Corticosteroids are the single most effective
herapy. Although there seems to be no advantage to
he combination with cyclosporine, this may reduce
ong-term complications of corticosteroids [35]. The
lternative use of tacrolimus with corticosteroids does
ot seem to offer any additional advantage in the
nitial treatment of chronic GVHD [39]. It is still
nclear whether intensifying initial therapy by ei-
her increasing steroid doses or incorporating new
gents into the initial combination of a calcineurin
nhibitor plus a corticosteroid will result in better
esponses, QOL, or survival. Two multicenter stud-
es (by A.L. Gilman, University of North Carolina
t Chapel Hill and P. J. Martin, Fred Hutchinson
ancer Research Center) are currently evaluating
he potential beneﬁts of hydroxychloroquine or my-
ophenolate mofetil added to the standard initial
orticosteroid therapy.
The second component of chronic GVHD ther-
py, occasionally overlooked, is ancillary and support-
ve care [7]. This includes education, prevention of
ares, infectious disease prophylaxis, physical and oc-
upational therapy, nutrition, alleviation of chronic
anifestations and effects of treatment, and promo-
ion of coping mechanisms or resources to help pa-
ients deal with the psychosocial, sexual, and ﬁnancial
onsequences of the disease. These interventions,
hen successful, may have the potential to reduce the
eed for systemic therapy. The relative impact of
hese interventions on the outcome of patients with
hronic GVHD needs further exploration.
Initial treatment with corticosteroids can control
hronic GVHD in about 50% of patients. Most of
hose without resolution of their chronic GVHD will
lso suffer the consequences of prolonged immuno-
uppression [34].
verview of Some Commonly used
econdary Treatments
Various new drugs and other immunomodulatory
reatments have shown activity in the salvage therapy
f chronic GVHD. This evidence originates in small
ilot and phase II studies, with doses and schedules
sually matching those of their FDA-approved use.
halidomide, sirolimus, extracorporeal photophere-
is, rituximab, pentostatin, mycophenolate mofetil,
ydroxychloroquine, and clofazimine are just some
xamples [2,18,40-43]. The overall response to salvage
herapy has ranged from 30% to  70%. Unfortu-
ately, with all these different therapies, the vast ma-
ority of the responses are partial, and the corticoste-
oids-sparing effect has not been systematically
ssessed or reported. The toxicity of some of these
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Advances in Chronic Graft-versus-Host Disease 9gents, such as thalidomide [43] and the combination
f sirolimus and tacrolimus [40], can be substantial. As
or initial therapy, the optimum salvage treatment
emains to be determined.
Evaluation of the role of newer immunomodulat-
ng, rather than immunosuppressant, therapies, aimed
t facilitating or inducing immune tolerance is cur-
ently underway.
ONCLUSION
The prevention and management of chronic
VHD remains at best unclear, and this complexity
eﬂects our need to understand the immunologic
echanisms of the disease. This underscores the im-
ortance of accrual into clinical studies at any stage of
he prevention and treatment of chronic GVHD. The
wareness of the magnitude of the disease, its diag-
ostic features, and organized criteria for assessing
reatment response and clinical trial design have been
reatly improved by the NIH Consensus Develop-
ent Project on Criteria for Clinical Trials in
hronic Graft-versus-Host Disease. This has set the
tage for multicenter collaborations to promote basic
nd clinical research toward maximizing disease-free
urvival without the burden of chronic GVHD.
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